Monoallelic deletion of <i>BCMA</i> is a frequent feature in multiple myeloma
Mehmet Samur(Dana-Farber Cancer Institute), Nikhil C. Munshi(Dana-Farber Cancer Institute), Hervé Avet‐Loiseau(Institut universitaire du cancer de Toulouse Oncopole), Anıl Aktaş Samur(Harvard University), Parth Shah(Dartmouth–Hitchcock Medical Center), Romain Lannes(Institut universitaire du cancer de Toulouse Oncopole), Kenneth Anderson(Harvard University), Jill Corre(Institut universitaire du cancer de Toulouse Oncopole)
Cited by 20
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k